These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 8247544)

  • 1. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.
    Juven T; Barak Y; Zauberman A; George DL; Oren M
    Oncogene; 1993 Dec; 8(12):3411-6. PubMed ID: 8247544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.
    Barak Y; Gottlieb E; Juven-Gershon T; Oren M
    Genes Dev; 1994 Aug; 8(15):1739-49. PubMed ID: 7958853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
    Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
    Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel p53 mutant retained functional activity in lung carcinomas.
    Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
    DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
    Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
    Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of transcriptional activation of mdm2 gene by p53 in response to UV radiation.
    Saucedo LJ; Carstens BP; Seavey SE; Albee LD; Perry ME
    Cell Growth Differ; 1998 Feb; 9(2):119-30. PubMed ID: 9486848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.
    Gudas JM; Nguyen H; Klein RC; Katayose D; Seth P; Cowan KH
    Clin Cancer Res; 1995 Jan; 1(1):71-80. PubMed ID: 9815889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-specific transcriptional activation of the mdm2-gene by ectopically expressed wild-type form of a temperature-sensitive mutant p53.
    Knippschild U; Kolzau T; Deppert W
    Oncogene; 1995 Aug; 11(4):683-90. PubMed ID: 7651732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
    Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
    Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mdm2 expression is induced by wild type p53 activity.
    Barak Y; Juven T; Haffner R; Oren M
    EMBO J; 1993 Feb; 12(2):461-8. PubMed ID: 8440237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 binds to a constitutively nucleosome free region of the mdm2 gene.
    Xiao G; White D; Bargonetti J
    Oncogene; 1998 Mar; 16(9):1171-81. PubMed ID: 9528859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
    Oliner JD; Pietenpol JA; Thiagalingam S; Gyuris J; Kinzler KW; Vogelstein B
    Nature; 1993 Apr; 362(6423):857-60. PubMed ID: 8479525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
    Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
    J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional p53-responsive intronic promoter is contained within the human mdm2 gene.
    Zauberman A; Flusberg D; Haupt Y; Barak Y; Oren M
    Nucleic Acids Res; 1995 Jul; 23(14):2584-92. PubMed ID: 7651818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y.
    Pospísilová S; Siligan C; Ban J; Jug G; Kovar H
    Mol Cancer Res; 2004 May; 2(5):296-304. PubMed ID: 15192123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.
    Lin J; Jin X; Page C; Sondak VK; Jiang G; Reynolds RK
    Cancer Res; 2000 Oct; 60(20):5895-901. PubMed ID: 11059788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
    Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
    Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants.
    Brown DR; Deb D; Frum R; Hickes L; Munoz R; Deb S; Deb SP
    Int J Oncol; 2001 Mar; 18(3):449-59. PubMed ID: 11179471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
    Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
    Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.